H. Lee Moffitt Cancer Center & Research Institute

Search Moffitt.org

Physician, Faculty, and Staff

Claudio Anasetti, MD

Claudio Anasetti, MD

Faculty Rank:

Senior Member

Titles:

  • Chair, Department of Blood & Marrow Transplant

Department/Program Affiliations:

  • Experimental Therapeutics
  • Blood & Marrow Transplant

Primary Address:

H. Lee Moffitt Cancer Center &
Research Institute
12902 Magnolia Drive
Tampa, FL 33612

Office:

(813) 745-2557

USF Affiliations/College Department:

  • Medicine / Oncologic Sciences

University Academic Rank:

Professor

For corrections, please e-mail a request

Printer friendly version
Printer friendly version (including publications)

Claudio Anasetti, MD

Education & Training:

  • M.D., University of Perugia, Italy, 1980 - School of Medicine
  • Residency, University of Perugia, Italy, 1982 - Internal Medicine
  • Fellowship, Children's Memorial Hospital, Oklahoma City, 1983 - Immunology
  • Fellowship, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, 1985 - Oncology

General Board Certification / SubSpecialty:

  • Internal Medicine / Medical Oncology

For corrections, please e-mail a request

Printer friendly version
Printer friendly version (including publications)

Claudio Anasetti, MD

Research Interests:

Antibody targeting of the T cell receptor and CD28 to prevent GVHD in mouse models and human transplants.

Clinical Interests:

Clinical blood and bone marrow transplantation; immunogenetics and donor selection; prevention and treatment of graft-versus-host disease.

For corrections, please e-mail a request

Printer friendly version
Printer friendly version (including publications)

Claudio Anasetti, MD

Publications:

  1. Perkins J, Field T, Kim J, Kharfan-Dabaja MA, Fernandez H, Ayala E, Perez L, Xu M, Alsina M, Ochoa L, Sullivan D, Janssen W, Anasetti C. A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant. 2010 Jan;. Pubmedid: 20102746.   Pubmed ID: 20102746

  2. Pidala J, Anasetti C, Jim H. Health-related quality of life following haematopoietic cell transplantation: patient education, evaluation and intervention. Br J Haematol. 2010 Feb;148(3):373-385. Pubmedid: 19919651.   Pubmed ID: 19919651

  3. Pidala J, Anasetti C. Glucocorticoid-refractory acute graft vs. Host disease. Biol Blood Marrow Transplant. 2010 Jan;. Pubmedid: 20096359.   Pubmed ID: 20096359

  4. Spellman S, Bray R, Rosen-Bronson S, Haagenson M, Klein J, Flesch S, Vierra-Green C, Anasetti C. The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure. Blood. 2010 Jan;. Pubmedid: 20089963.   Pubmed ID: 20089963

  5. Anasetti C. Selecting donor recipients. Biol Blood Marrow Transplant. 2009 Mar;15(3):393-394. Pubmedid: 19203734.   Pubmed ID: 19203734

  6. Carnevale-Schianca F, Leisenring W, Martin PJ, Furlong T, Schoch G, Anasetti C, Appelbaum FR, Carpenter PA, Deeg HJ, Kiem HP, Storb R, McDonald GB, Nash RA. Longitudinal assessment of morbidity and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation: retrospective analysis of a multicenter phase III study. Biol Blood Marrow Transplant. 2009 Jun;15(6):749-756. Pubmedid: 19450760. Pmcid: PMC2684865.   Pubmed ID: 19450760

  7. Davies SM, Wang D, Wang T, Arora M, Ringden O, Anasetti C, Pavletic S, Casper J, Macmillan ML, Sanders J, Wall D, Kernan NA. Recent decrease in acute graft-versus-host disease in children with leukemia receiving unrelated donor bone marrow transplants. Biol Blood Marrow Transplant. 2009 Mar;15(3):360-366. Pubmedid: 19203727.   Pubmed ID: 19203727

  8. Field T, Perkins J, Huang Y, Kharfan-Dabaja MA, Alsina M, Ayala E, Fernandez HF, Janssen W, Lancet J, Perez L, Sullivan D, List A, Anasetti C. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2009 Jun;. Pubmedid: 19543327.   Pubmed ID: 19543327

  9. Gajewski JL, LeMaistre CF, Silver SM, Lill MC, Selby GB, Horowitz MM, Rizzo JD, Heslop HE, Anasetti C, Maziarz RT. Impending challenges in the hematopoietic stem cell transplantation physician workforce. Biol Blood Marrow Transplant. 2009 Dec;15(12):1493-1501. Pubmedid: 19781658.   Pubmed ID: 19781658

  10. Iclozan C, Yu Y, Liu C, Liang Y, Yi T, Anasetti C, Yu XZ. Th17 cells are sufficient but not necessary to induce acute graft-versus-host disease. Biol Blood Marrow Transplant. 2009 Oct;. Pubmedid: 19804837.   Pubmed ID: 19804837

  11. Perez LE, Parquet N, Meads M, Anasetti C, Dalton W. Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myeloma. Eur J Haematol. 2009 Nov;. Pubmedid: 19922463.   Pubmed ID: 19922463

  12. Pidala J, Anasetti C, Jim H. Quality of life after allogeneic hematopoietic cell transplantation. Blood. 2009 Jul;114(1):7-19. Pubmedid: 19336756.   Pubmed ID: 19336756

  13. Pidala J, Anasetti C, Kharfan-Dabaja MA, Cutler C, Sheldon A, Djulbegovic B. Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2009 Nov;15(11):1415-1421. Pubmedid: 19822301.   Pubmed ID: 19822301

  14. Pidala J, Anasetti C. Can antigen-specific regulatory T cells protect against graft vs. host disease and spare anti-malignancy alloresponse?. Haematologica. 2009 Dec;. Pubmedid: 20015881.   Pubmed ID: 20015881

  15. Pidala J, Bloom GC, Enkemann S, Eschrich S, Lancaster J, Anasetti C. Biomarkers to discern transplantation tolerance after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2009 Nov;. Pubmedid: 19922809.   Pubmed ID: 19922809

  16. Pidala J, Kim J, Anasetti C. Sirolimus as Primary Treatment of Acute Graft-versus-Host Disease following Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2009 Jul;15(7):881-885. Pubmedid: 19539221.   Pubmed ID: 19539221

  17. Pidala J, Kim J, Field T, McBride A, Kharfan-Dabaja M, Perkins J, Fernandez H, Perez L, Ayala E, Anasetti C. Infliximab for managing steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2009 Sep;15(9):1116-1121. Pubmedid: 19660725.   Pubmed ID: 19660725

  18. Pidala J, Kim J, Perkins J, Field T, Fernandez H, Perez L, Ayala E, Kharfan-Dabaja M, Anasetti C. Mycophenolate mofetil for the management of steroid-refractory acute graft vs host disease. Bone Marrow Transplant. 2009 Sep;. Pubmedid: 19767783.   Pubmed ID: 19767783

  19. Ringden O, Pavletic SZ, Anasetti C, Barrett AJ, Wang T, Wang D, Antin JH, Di Bartolomeo P, Bolwell BJ, Bredeson C, Cairo MS, Gale RP, Gupta V, Hahn T, Hale GA, Halter J, Jagasia M, Litzow MR, Locatelli F, Marks DI, McCarthy PL, Cowan MJ, Petersdorf EW, Russell JA, Schiller GJ, Schouten H, Spellman S, Verdonck LF, Wingard JR, Horowitz MM, Arora M. The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood. 2009 Mar;113(13):3110-3118. Pubmedid: 19059878.   Pubmed ID: 19059878

  20. Salinger DH, Blough DK, Vicini P, Anasetti C, O'Donnell PV, Sandmaier BM, McCune JS. A Limited Sampling Schedule to Estimate Individual Pharmacokinetic Parameters of Fludarabine in Hematopoietic Cell Transplant Patients. Clin Cancer Res. 2009 Aug;15(16):5280-5287. Pubmedid: 19671874.   Pubmed ID: 19671874

  21. Yu Y, Iclozan C, Yamazaki T, Yang X, Anasetti C, Dong C, Yu XZ. Abundant c-Fas expression determines resistance of T helper 17 cells to activation-induced cell death. Blood. 2009 Jul;114(5):1026-1028. Pubmedid: 19429865.   Pubmed ID: 19429865

  22. Anasetti C. Chemotherapy or allografting for young adults with high-risk ALL. Blood. 2008 Jun;111(12):5755-5755. Pubmedid: 18544698.   Pubmed ID: 18544698

  23. Anasetti C. What are the most important donor and recipient factors affecting the outcome of related and unrelated allogeneic transplantation. Best Pract Res Clin Haematol. 2008 Dec;21(4):691-697. Pubmedid: 19041609.   Pubmed ID: 19041609

  24. Guo F, Iclozan C, Suh WK, Anasetti C, Yu XZ. CD28 controls differentiation of regulatory T cells from naive CD4 T cells. J Immunol. 2008 Aug;181(4):2285-2291. Pubmedid: 18684917.   Pubmed ID: 18684917

  25. Hahn T, McCarthy PL , Zhang MJ, Wang D, Arora M, Frangoul H, Gale RP, Hale GA, Horan J, Isola L, Maziarz RT, van Rood JJ, Gupta V, Halter J, Reddy V, Tiberghien P, Litzow M, Anasetti C, Pavletic S, Ringden O. Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. J Clin Oncol. 2008 Dec;26(35):5728-5734. Pubmedid: 18981462.   Pubmed ID: 18981462

  26. Kamani N, Spellman S, Hurley C, Barker J, Smith F, Oudshoorn M, Bray R, Smith A, Williams T, Logan B, Eapen M, Anasetti C, Setterholm M, Confer D. State of the art review: HLA matching and outcome of unrelated donor umbilical cord blood transplants. Biol Blood Marrow Transplant. 2008 Jan;14(1):1-6. Pubmedid: 18158954.   Pubmed ID: 18158954

  27. Liang Y, Liu C, Djeu JY, Zhong B, Peters T, Scharffetter-Kochanek K, Anasetti C, Yu XZ. Beta2 integrins separates graft-versus-host disease and graft-versus-leukemia effects. Blood. 2008 Jan;111(2):954-962. Pubmedid: 17928532.   Pubmed ID: 17928532

  28. Perez L, Parquet N, Shain K, Nimmanapalli R, Alsina M, Anasetti C, Dalton W. Bone Marrow Stroma Confers Resistance to Apo2 Ligand/TRAIL in Multiple Myeloma inPart by Regulating c-FLIP. J Immunol. 2008 Feb;180(3):1545-1555. Pubmedid: 18209050.   Pubmed ID: 18209050

  29. Weisdorf D, Spellman S, Haagenson M, Horowitz M, Lee S, Anasetti C, Setterholm M, Drexler R, Maiers M, King R, Confer D, Klein J. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood Marrow Transplant. 2008 Jul;14(7):748-758. Pubmedid: 18541193.   Pubmed ID: 18541193

  30. Anasetti C, Mule JJ. To ablate or not to ablate? HSCs in the T cell driver's seat. J Clin Invest. 2007 Feb;117(2):306-310. Pubmedid: 17273553.   Pubmed ID: 17273553

  31. Eapen M, Logan BR, Confer DL, Haagenson M, Wagner JE, Weisdorf DJ, Wingard JR, Rowley SD, Stroncek D, Gee AP, Horowitz MM, Anasetti C. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transplant. 2007 Dec;13(12):1461-1468. Pubmedid: 18022576.   Pubmed ID: 18022576

  32. Ferrara J, Anasetti C, Stadtmauer E, Antin J, Wingard J, Lee S, Levine J, Schultz K, Appelbaum F, Negrin R, Giralt S, Bredeson C, Heslop H, Horowitz M. Blood and marrow transplant clinical trials network state of the science symposium 2007. Biol Blood Marrow Transplant. 2007 Nov;13(11):1268-1285. Pubmedid: 17950914.   Pubmed ID: 17950914

  33. Jacobs S, Jacobsen P, Booth-Jones M, Wagner L, Anasetti C. Evaluation of the functional assessment of cancer therapy cognitive scale with hematopoietic stem cell transplant patients. J Pain Symptom Manage. 2007 Jan;33(1):13-23. Pubmedid: 17196903.   Pubmed ID: 17196903

  34. Kharfan-Dabaja M, Anasetti C, Ferrara J. Sympathectomy protects denervated skin from graft-versus-host disease. Biol Blood Marrow Transplant. 2007 Mar;13(3):369-370. Pubmedid: 17317591.   Pubmed ID: 17317591

  35. Kharfan-Dabaja M, Anasetti C, Santos E. Hematopoietic cell transplantation for chronic lymphocytic leukemia: an evolving concept. Biol Blood Marrow Transplant. 2007 Apr;13(4):373-385. Pubmedid: 17382245.   Pubmed ID: 17382245

  36. Kharfan-Dabaja M, Ayala E, Greene J, Rojiani A, Murtagh F, Anasetti C. Two cases of progressive multifocal leukoencephalopathy after allogeneic hematopoietic cell transplantation and a review of the literature. Bone Marrow Transplant. 2007 Jan;39(2): 101-7. Pubmedid: 17143300.   Pubmed ID: 17143300

  37. Kharfan-Dabaja MA, Ayala E, Greene J, Rojiani A, Murtagh F, Anasetti C. Two cases of progressive multifocal leukoencephalopathy after allogeneic hematopoietic cell transplantation and a review of the literature. Bone Marrow Transplant. 2007 Feb;39(4):253-254. Pubmedid: 17290282.   Pubmed ID: 17290282

  38. Lee S, Klein J, Haagenson M, Baxter-Lowe L, Confer D, Eapen M, Fernandez-Vina M, Flomenberg N, Horowitz M, Hurley C, Noreen H, Oudshoorn M, Petersdorf E, Setterholm M, Spellman S, Weisdorf D, Williams T, Anasetti C. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007 Dec;110(13):4576-4583. Pubmedid: 17785583.   Pubmed ID: 17785583

  39. Albert M, Anasetti C, Yu X. T regulatory cells as an immunotherapy for transplantation. Expert Opin Biol Ther. 2006 Apr;6(4):315-324. Pubmedid: 16548760.   Pubmed ID: 16548760

  40. Anasetti C, Perkins J, Nieder M, Field T. Are matched unrelated donor transplants justified for AML in CR1. Best Pract Res Clin Haematol. 2006;19(2):321-328. Pubmedid: 16516129.   Pubmed ID: 16516129

  41. Anasetti C. The 2006 BBMT Education Supplement. Biol Blood Marrow Transplant. 2006 Jan;12(1):1-1. Pubmedid: 16399576.   Pubmed ID: 16399576

  42. Deeg H, Storer B, Boeckh M, Martin P, McCune J, Myerson D, Heimfeld S, Flowers M, Anasetti C, Doney K, Hansen J, Kiem H, Nash R, O'donnell P, Radich J, Sandmaier B, Scott B, Sorror M, Warren E, Witherspoon R, Woolfrey A, Appelbaum F, Storb R. Reduced Incidence of Acute and Chronic Graft-versus-Host Disease with the Addition of Thymoglobulin to a Targeted Busulfan/Cyclophosphamide Regimen. Biol Blood Marrow Transplant. 2006 May;12(5):573-584. Pubmedid: 16635793.   Pubmed ID: 16635793

  43. Farag S, Bacigalupo A, Eapen M, Hurley C, Dupont B, Caligiuri M, Boudreau C, Nelson G, Oudshoorn M, van Rood J, Velardi A, Maiers M, Setterholm M, Confer D, Posch P, Anasetti C, Kamani N, Miller J, Weisdorf D, Davies S. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2006 Aug;12(8):876-884. Pubmedid: 16864058.   Pubmed ID: 16864058

  44. Green M, Anasetti C, Sandin R, Rolfe N, Greene J. Development of daptomycin resistance in a bone marrow transplant patient with vancomycin-resistant Enterococcus durans. J Oncol Pharm Pract. 2006 Sep;12(3):179-181. Pubmedid: 17022872.   Pubmed ID: 17022872

  45. Jones R, Anasetti C, Appel P, Dipersio J, Heslop H, Lemaistre F, Silver S, Sirilla J, Stiff P. White paper on measurement of quality outcomes. Biol Blood Marrow Transplant. 2006 May;12(5):594-597. Pubmedid: 16635795.   Pubmed ID: 16635795

  46. Yu X, Albert M, Anasetti C. Alloantigen Affinity and CD4 Help Determine Severity of Graft-versus-Host Disease Mediated by CD8 Donor T Cells. J Immunol. 2006 Mar;176(6):3383-3390. Pubmedid: 16517706.   Pubmed ID: 16517706

  47. Yu X, Liang Y, Nurieva R, Guo F, Anasetti C, Dong C. Opposing effects of ICOS on graft-versus-host disease mediated by CD4 and CD8 T cells. J Immunol. 2006 Jun;176(12):7394-7401. Pubmedid: 16751384.   Pubmed ID: 16751384

  48. Albert M, Liu Y, Anasetti C, Yu X. Antigen-dependent suppression of alloresponses by Foxp3-induced regulatory T cells in transplantation. Eur J Immunol. 2005 Oct;35(9):2598-2607. Pubmedid: 16078276.   Pubmed ID: 16078276

  49. Albert M, Yu X, Martin P, Anasetti C. Prevention of lethal acute GVHD with an agonistic CD28 antibody and rapamycin. Blood. 2005 Feb;105(3):1355-1361. Pubmedid: 15459004.   Pubmed ID: 15459004

  50. Carpenter P, Lowder J, Johnston L, Frangoul H, Khoury H, Parker P, JeromeKR, McCune J, Storer B, Martin P, Appelbaum F, Abonour R, Westervelt P, Anasetti C. A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2005 Jun;11(6):465-471. Pubmedid: 15931635.   Pubmed ID: 15931635

  51. Field T, Anasetti C. Selection of unrelated donors for hematopoietic cell transplantation. Curr Hematol Rep. 2005 Jul;4(4):270-275. Pubmedid: 16009041.   Pubmed ID: 16009041

  52. Nash R, Johnston L, Parker P, McCune J, Storer B, Slattery J, Furlong T, Anasetti C, Appelbaum F, Lloid M, Deeg H, Kiem H, Martin P, Schubert M, Witherspoon R, Forman S, Blume K, Storb R. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2005;11(7):495-505. Pubmedid: 15983549.   Pubmed ID: 15983549

  53. Pavletic S, Khouri I, Haagenson M, King R, Bierman P, Bishop M, Carston M, Giralt S, Molina A, Copelan E, Ringden O, Roy V, Ballen K, Adkins DR, McCarthy P, Weisdorf D, Montserrat E, Anasetti C. Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant Research. J Clin Oncol. 2005 Aug;23(24):5788-5794. Pubmedid: 16043827.   Pubmed ID: 16043827

  54. Yu X, Anasetti C. Memory stem cells sustain disease. Nat Med. 2005 Dec;11(12):1282-1283. Pubmedid: 16333266.   Pubmed ID: 16333266

  55. Anasetti C. Advances in the prevention of graft-versus-host disease after hematopoietic cell transplantation. Transplantation. 2004;77(9):S79-S83. Pubmedid: 15201691.   Pubmed ID: 15201691

  56. Cutler C, Lee S, Greenberg P, Deeg H, Perez W, Anasetti C, Bolwell B, Cairo M, Gale R, Klein J, Lazarus H, Liesveld J, McCarthy P, Milone G, Rizzo J, Schultz K, Trigg M, Keating A, Weisdorf D, Antin J, Horowitz M. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasiais associated with improved outcome. Blood. 2004;104(2):579-585. Pubmedid: 15039286.   Pubmed ID: 15039286

  57. Flomenberg N, Baxter-Lowe L, Confer D, Fernandez-Vina M, Filipovich A, Horowitz M, Hurley C, Kollman C, Anasetti C, Noreen H, Begovich A, Hildebrand W, Petersdorf E, Schmeckpeper B, Setterholm M, Trachtenberg E, Williams T, Yunis E, Weisdorf D. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood. 2004;104(7):1923-1930. Pubmedid: 15191952.   Pubmed ID: 15191952

  58. Martin P, McDonald G, Sanders J, Anasetti C, Appelbaum F, Deeg H, NashRA, Petersdorf E, Hansen J, Storb R. Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2004;10(5):320-327. Pubmedid: 15111931.   Pubmed ID: 15111931

  59. Martin P, Pei J, Gooley T, Anasetti C, Appelbaum F, Deeg J, Hansen J, Nash R, Petersdorf E, Storb R, Ghetie V, Schindler J, Vitetta E. Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation. Biol Blood Marrow Transplant. 2004;10(8):552-560. Pubmedid: 15282533.   Pubmed ID: 15282533

  60. Petersdorf E, Anasetti C, Martin P, Gooley T, Radich J, Malkki M, WoolfreyA, Smith A, Mickelson E, Hansen J. Limits of HLA mismatching in unrelated hematopoietic cell transplantation. Blood. 2004;104(9):2976-2980. Pubmedid: 15251989.   Pubmed ID: 15251989

  61. Stewart B, Storer B, Storek J, Deeg H, Storb R, Hansen J, Appelbaum F, Carpenter P, Sanders J, Kiem H, Nash R, Petersdorf E, Moravec C, Morton A, Anasetti C, Flowers M, Martin P. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood. 2004;104(12):3501-3506. Pubmedid: 15292060.   Pubmed ID: 15292060

  62. Yu XZ, Albert MH, Martin PJ, Anasetti C. CD28 ligation induces transplantation tolerance by IFNg-dependent depletion of T cells that recognize alloantigens. J Clin Invest. 2004 Jun;113(11):1624-1630. Pubmedid: 15173889.   Pubmed ID: 15173889

  63. Yu XZ, Levin SD, Madrenas J, Anasetti C. Lck is required for activation-induced T cell death after TCR ligation with partial agonists. J Immunol. 2004 Feb;172(3):1437-1443. Pubmedid: 14734719.   Pubmed ID: 14734719

  64. Anasetti C. Acquired tolerance to renal allografts in humans. Am J Transplant. 2003;3(3):243-244. Pubmedid: 12614276.   Pubmed ID: 12614276

  65. Anasetti C. Advances in unrelated donor hematopoietic cell transplantation. Haematologica. 2003;88(3):246-249. Pubmedid: 12651260.   Pubmed ID: 12651260

  66. Arpinati M, Chirumbolo G, Urbini B, Perrone G, Rondelli D, Anasetti C. Role of plasmacytoid dendritic cells in immunity and tolerance after allogeneic hematopoietic stem cell transplantation. Transpl Immunol. 2003;11(3-4):345-356. Pubmedid: 12967787.   Pubmed ID: 12967787

  67. Bornhauser M, Storer B, Slattery J, Appelbaum F, Deeg H, Hansen J, Martin P, McDonald G, Nichols W, Radich J, Woolfrey A, Jenke A, Schleyer E, Thiede C, Ehninger G, Anasetti C. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood. 2003;102(3):820-826. Pubmedid: 12676781.   Pubmed ID: 12676781

  68. Deeg H, Gooley T, Flowers M, Sale G, Slattery J, Anasetti C, ChaunceyTR, Doney K, Georges G, Kiem H, Martin P, Petersdorf E, Radich J, SandersJE, Sandmaier B, Warren E, Witherspoon R, Storb R, Appelbaum F. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood. 2003;102(12):3912-3918. Pubmedid: 12920019.   Pubmed ID: 12920019

  69. Hurley C, Baxter Lowe L, Logan B, Karanes C, Anasetti C, Weisdorf D, Confer D. National Marrow Donor Program HLA-matching guidelines for unrelated marrow transplants. Biol Blood Marrow Transplant. 2003;9(10):610-615. Pubmedid: 14569557.   Pubmed ID: 14569557

  70. Maris M, Niederwieser D, Sandmaier B, Storer B, Stuart M, Maloney D, Petersdorf E, McSweeney P, Pulsipher M, Woolfrey A, Chauncey T, Agura E, Heimfeld S, Slattery J, Hegenbart U, Anasetti C, Blume K, Storb R. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood. 2003;102(6):2021-2030. Pubmedid: 12791654.   Pubmed ID: 12791654

  71. McDonald GB, Slattery JT, Bouvier ME, Ren S, Batchelder AL, Kalhorn TF, Schoch HG, Anasetti C, Gooley T. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood. 2003 Mar;101(5):2043-2048. Pubmedid: 12406916.   Pubmed ID: 12406916

  72. Niederwieser D, Maris M, Shizuru J, Petersdorf E, Hegenbart U, SandmaierBM, Maloney D, Storer B, Lange T, Chauncey T, Deininger M, Ponisch W, Anasetti C, Woolfrey A, Little M, Blume K, McSweeney P, Storb R. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression. Blood. 2003;101(4):1620-1629. Pubmedid: 12393457.   Pubmed ID: 12393457

  73. Yu X, Martin P, Anasetti C. CD28 signal enhances apoptosis of CD8 T cells after strong TCR ligation. J Immunol. 2003;170(6):3002-3006. Pubmedid: 12626553.   Pubmed ID: 12626553

  74. Anasetti C. Advances in unrelated donor hematopoietic cell transplantation: improved matching and use of blood stem cells. Haematologica. 2002;87:1-3. Pubmedid: 12412381.   Pubmed ID: 12412381

  75. Carpenter P, Appelbaum F, Corey L, Deeg H, Doney K, Gooley T, Krueger J, Martin P, Pavlovic S, Sanders J, Slattery J, Levitt D, Storb R, Woolfrey A, Anasetti C. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood. 2002;99(8):2712-2719. Pubmedid: 11929757.   Pubmed ID: 11929757

  76. Deeg H, Storer B, Slattery J, Anasetti C, Doney K, Hansen J, Kiem H, Martin P, Petersdorf E, Radich J, Sanders J, Shulman H, Warren E, Witherspoon R, Bryant E, Chauncey T, Getzendaner L, Storb R, Appelbaum F. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood. 2002;100(4):1201-1207. Pubmedid: 12149198.   Pubmed ID: 12149198

  77. Furlong T, Leisenring W, Storb R, Anasetti C, Appelbaum F, Carpenter P, Deeg H, Doney K, Kiem H, Nash R, Sanders J, Witherspoon R, Thompson D, Martin P. Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease. Biol Blood Marrow Transplant. 2002;8(4):206-212. Pubmedid: 12014809.   Pubmed ID: 12014809

  78. Jurado M, Deeg H, Storer B, Anasetti C, Anderson J, Bryant E, Chauncey T, Doney K, Flowers M, Hansen J, Martin P, Nash R, Petersdorf E, Radich J, SaleG, Sandmaier B, Storb R, Wade J, Witherspoon R, Appelhaum F. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. Biol Blood Marrow Transplant. 2002;8(3):161-169. Pubmedid: 11939606.   Pubmed ID: 11939606

  79. Koc S, Leisenring W, Flowers M, Anasetti C, Deeg H, Nash R, Sanders J, Witherspoon R, Storb R, Appelbaum F, Martin P. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood. 2002;100(1):48-51. Pubmedid: 12070007.   Pubmed ID: 12070007

  80. Platzbecker U, Gooley T, Anasetti C, Appelbaum F, Clurman B, Doney K, Chauncey T, Flowers M, Myerson D, Radich J, Storb R, Witherspoon R, Deeg H. Curative therapy of advanced essential thrombocythemia or polycythemia vera by hemopoietic stem cell transplantation. Leuk Lymphoma. 2002;43(7):1409-1414. Pubmedid: 12389621.   Pubmed ID: 12389621

  81. Rossi M, Arpinati M, Rondelli D, Anasetti C. Plasmacytoid dendritic cells: do they have a role in immune responses after hematopoietic cell transplantation. Hum Immunol. 2002;63(12):1194-1200. Pubmedid: 12480263.   Pubmed ID: 12480263

  82. Tan P, Mitchell D, Buss T, Holmes M, Anasetti C, Foote J. "Superhumanized" antibodies: reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences: application to an anti-CD28. J Immunol. 2002;169(2):1119-1125. Pubmedid: 12097421.   Pubmed ID: 12097421

  83. Weisdorf D, Anasetti C, Antin J, Kernan N, Kollman C, Snyder D, Petersdorf E, Nelson G, McGlave P. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood. 2002;99(6):1971-1977. Pubmedid: 11877268.   Pubmed ID: 11877268

  84. Woolfrey A, Anasetti C, Storer B, Doney K, Milner L, Sievers E, Carpenter P, Martin P, Petersdorf E, Appelbaum F, Hansen J, Sanders J. Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children. Blood. 2002;99(6):2002-2008. Pubmedid: 11877272.   Pubmed ID: 11877272

  85. Arpinati M, Green C, Heimfeld S, Heuser J, Anasetti C. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood. 2000;95(8):2484-2490. Pubmedid: 10753825.   Pubmed ID: 10753825

  86. Deeg H, Shulman H, Anderson J, Bryant E, Gooley T, Slattery J, Anasetti C, Fefer A, Storb R, Appelbaum F. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood. 2000;95(4):1188-1194. Pubmedid: 10666189.   Pubmed ID: 10666189

  87. Yu X, Anasetti C. Enahancement of susceptibility to Fas-mediated apoptosis of TH1 cells by nonmitogenic anti-CD3epsilon F(ab')2. Transplantation. 2000;69(1):104-112. Pubmedid: 10653388.   Pubmed ID: 10653388

Claudio Anasetti, MD

Below is a list of active grants where the faculty member is the Principal Investigator. Grants are sorted by sponsor and then sorted by start date, with the more recent grant shown first.

Antigen Specific T Cell Tolerance by Anti CD3 Antibodies

5 R01 CA132197-07
Sponsor: Nat Institutes of Health / NCI
Project Dates: May 1, 2004 to July 31, 2013
Annual Direct Cost: $224,016
Annual Total Cost: $374,107
Project Total: $1,911,524

Peripheral T Cell Tolerance by Targeting AKT

1 R21 AI082498-01
Sponsor: Nat Institutes of Health / NIAID
Project Dates: May 15, 2009 to April 30, 2011
Annual Direct Cost: $150,000
Annual Total Cost: $250,250
Project Total: $459,000

Busulfan Dose Escalation Study Based on Area under the AUC Allogeneic Hematopoietic Cell l Transplantation (NO COST EXTENSION)
Sponsor: PDL BioPharma, Inc.
Project Dates: February 12, 2007 to February 11, 2010

Physician/Faculty  Contact Form

© Copyright 1996 - 2010 H. Lee Moffitt Cancer Center & Research Institute